Esther Rajavelu
Stock Analyst at UBS
(0.69)
# 3,927
Out of 4,955 analysts
26
Total ratings
46.15%
Success rate
-22.85%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Esther Rajavelu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Maintains: Neutral | $45 → $46 | $42.81 | +7.45% | 4 | Aug 12, 2025 | |
| APLT Applied Therapeutics | Downgrades: Neutral | $13 → $2 | $0.50 | +300.48% | 3 | Dec 2, 2024 | |
| DNLI Denali Therapeutics | Maintains: Buy | $70 → $32 | $14.52 | +120.39% | 2 | Apr 9, 2024 | |
| ALNY Alnylam Pharmaceuticals | Upgrades: Buy | $141 → $215 | $458.31 | -53.09% | 5 | Oct 4, 2021 | |
| RARE Ultragenyx Pharmaceutical | Initiates: Sell | $73 | $29.36 | +148.64% | 1 | Aug 19, 2021 | |
| BHVN Biohaven | Downgrades: Neutral | $108 → $109 | $14.70 | +641.50% | 6 | Aug 10, 2021 | |
| STOK Stoke Therapeutics | Initiates: Neutral | $35 | $19.32 | +81.16% | 1 | May 18, 2021 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $174 → $228 | $119.07 | +91.48% | 1 | Mar 1, 2021 | |
| ARWR Arrowhead Pharmaceuticals | Initiates: Perform | n/a | $20.20 | - | 1 | Dec 13, 2019 | |
| INVA Innoviva | Initiates: Hold | $13 | $19.95 | -34.84% | 1 | Nov 20, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $1.10 | +809.09% | 1 | Jul 21, 2017 |
Ionis Pharmaceuticals
Aug 12, 2025
Maintains: Neutral
Price Target: $45 → $46
Current: $42.81
Upside: +7.45%
Applied Therapeutics
Dec 2, 2024
Downgrades: Neutral
Price Target: $13 → $2
Current: $0.50
Upside: +300.48%
Denali Therapeutics
Apr 9, 2024
Maintains: Buy
Price Target: $70 → $32
Current: $14.52
Upside: +120.39%
Alnylam Pharmaceuticals
Oct 4, 2021
Upgrades: Buy
Price Target: $141 → $215
Current: $458.31
Upside: -53.09%
Ultragenyx Pharmaceutical
Aug 19, 2021
Initiates: Sell
Price Target: $73
Current: $29.36
Upside: +148.64%
Biohaven
Aug 10, 2021
Downgrades: Neutral
Price Target: $108 → $109
Current: $14.70
Upside: +641.50%
Stoke Therapeutics
May 18, 2021
Initiates: Neutral
Price Target: $35
Current: $19.32
Upside: +81.16%
Jazz Pharmaceuticals
Mar 1, 2021
Maintains: Buy
Price Target: $174 → $228
Current: $119.07
Upside: +91.48%
Arrowhead Pharmaceuticals
Dec 13, 2019
Initiates: Perform
Price Target: n/a
Current: $20.20
Upside: -
Innoviva
Nov 20, 2017
Initiates: Hold
Price Target: $13
Current: $19.95
Upside: -34.84%
Jul 21, 2017
Initiates: Buy
Price Target: $10
Current: $1.10
Upside: +809.09%